







an Open Access Journal by MDPI

The Cancer Proteome

Guest Editor:

Prof. Dr. Samir M. Hanash

Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Deadline for manuscript submissions:

closed (30 September 2020)

Message from the Guest Editor

Dear Colleagues,

Interest in the cancer proteome has accelerated substantially driven by the need to elucidate altered protein expression at the tumor cell level on a compartment-by-compartment basis; this includes analyses involving the secretome, exosomes, surfaceome, immunopeptidome, phosphoproteome, glycoproteome, and other post-translational modifications. Likewise, there a need to elucidate changes in the tumor microenvironment that drive tumor development and progression, and to identify prognostic and predictive markers as well as novel targets for therapy, particularly antigens relevant to immunotherapy and vaccine development. This Special Issue intends to showcase many of the numerous facets of the cancer proteome and related translational applications and innovative technologies.

Prof. Dr. Samir M. Hanash Guest Editor













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us